{"filing":{"accession_number":"0001493152-26-030190","cik":"0001716166","ticker":"VVOS","company_name":"Vivos Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226030190/form8-k.htm"},"events":[{"id":14029,"run_id":12475,"accession_number":"0001493152-26-030190","anchor_item_number":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.65,"summary":"The filing discloses entry into a Letter Agreement amending a prior Exchange Agreement with Streeterville Capital, extending the deadline for completing a qualifying financing from June 15 to August 31, 2026. The core transaction involves conversion of up to $4.5 million of outstanding indebtedness into preferred and common stock, contingent on the Company raising $2.6 million in new equity. While this is fundamentally a debt restructuring (debt-to-equity conversion), the Item 1.01 classification and the emphasis on the financing requirement and equity raise suggest the event centers on the capital structure modification and refinancing obligation rather than a pure debt issuance. The materiality is clear given the company's stated need to maintain Nasdaq listing compliance and strengthen stockholders' equity.","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":11341,"accession_number":"0001493152-26-030190","item_number":null,"item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.65,"reasoning":"The filing discloses entry into a Letter Agreement amending a prior Exchange Agreement with Streeterville Capital, extending the deadline for completing a qualifying financing from June 15 to August 31, 2026. The core transaction involves conversion of up to $4.5 million of outstanding indebtedness into preferred and common stock, contingent on the Company raising $2.6 million in new equity. While this is fundamentally a debt restructuring (debt-to-equity conversion), the Item 1.01 classification and the emphasis on the financing requirement and equity raise suggest the event centers on the capital structure modification and refinancing obligation rather than a pure debt issuance. The materiality is clear given the company's stated need to maintain Nasdaq listing compliance and strengthen stockholders' equity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:23:40.889904+00:00","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-06-25"}]}